The control of keratinocyte, fibroblast, and endothelial cell (EC) migration behavior are important steps in dermal wound healing. In this proposal, we hypothesize that heparan sulfate (HS), as a plurifunctional glycoasminoglycan which can act as a reservoir for dermal cell chemoattractants and mitogens, including FGF-1 and FGF-2, establishes an important biomimetic paradigm for the generation of neoglycopolymers with tailored biological and structural properties for use in controlled regeneration of the skin. We anticipate that these model materials will also provide important tools for defining the molecular mechanisms which control the behavior of dermal fibroblasts, ECs, and keratinocytes on natural, as well as synthetic surfaces. Specifically, we intend to: 1) Synthesize and characterize heparan sulfate based glycopolymers as synthetic matrix components which potentiate receptor specific activities of FGF-1 and FGF-2. Heparan-sulfate mimicking glycopolymers will be synthesized utilizing vinyl functionalized oligosaccharide monomers. Confirmation of polymer structure will be obtained by 1H and 13C NMR, IR spectroscopy, and gel permeation chromatography. FGF-1 and FGF-2 binding and receptor activating properties will be investigated using both cellular and cell free systems. The capacity of soluble HS-mimetic glycopolymers to enhance the proliferative and migratory properties of keratinocytes and fibroblasts, as well as dermal microvascular endothelial cells will be defined in vitro. 2) Define the biomimetic material properties of neoglycopolymer/gelatin matrices which mediate dermal and epidermal cell migration and proliferation in vitro. Glycopolymer/gelatin blends will be formulated. The ability of these matrix formulations, with or without added FGF-1 and FGF-2, to modulate the adhesive, proliferative, and migratory properties of keratinocytes and fibroblasts, as well as dermal microvascular endothelial cells will be determined.

Project Start
1999-05-01
Project End
2000-04-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
6
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Emory University
Department
Type
DUNS #
042250712
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Arbiser, Jack L; Bonner, Michael Y; Gilbert, Linda C (2017) Targeting the duality of cancer. NPJ Precis Oncol 1:
Pleniceanu, Oren; Shukrun, Racheli; Omer, Dorit et al. (2017) Peroxisome proliferator-activated receptor gamma (PPAR?) is central to the initiation and propagation of human angiomyolipoma, suggesting its potential as a therapeutic target EMBO Mol Med 9:508-530
Díaz, Begoña; Ostapoff, Katherine T; Toombs, Jason E et al. (2016) Tris DBA palladium is highly effective against growth and metastasis of pancreatic cancer in an orthotopic model. Oncotarget 7:51569-51580
Laidlaw, Kamilla M E; Berhan, Samuel; Liu, Suhu et al. (2016) Cooperation of imipramine blue and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia. Oncotarget 7:51651-51664
Bhandarkar, Sulochana S; Lanka, Padmavathy; Lanka, Lakshmana Rao et al. (2016) Tuberculosis verrucosa cutis lesions exhibit a greater microvessel count than lupus vulgaris lesions. Exp Dermatol 25:479-80
Costa, Adilson; Bonner, Michael Yi; Arbiser, Jack L (2016) Use of Polyphenolic Compounds in Dermatologic Oncology. Am J Clin Dermatol 17:369-85
Bonner, Michael Y; Karlsson, Isabella; Rodolfo, Monica et al. (2016) Honokiol bis-dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant melanoma in vivo. Oncotarget 7:12857-68
Arbiser, Jack L; Bonner, Michael Y (2016) Seborrheic Keratoses: The Rodney Dangerfield of Skin lesions, and Why They Should Get Our Respect. J Invest Dermatol 136:564-566
Arbiser, Jack L (2014) PHIPing out: a genetic basis for tumor ulceration. J Invest Dermatol 134:600-602
Spence-Shishido, Allyson; Carr, Christopher; Bonner, Michael Y et al. (2013) In vivo Gram staining of tinea versicolor. JAMA Dermatol 149:991-2

Showing the most recent 10 out of 131 publications